CB2-selective cannabinoid receptor ligands: Synthesis, pharmacological evaluation, and molecular modeling investigation of 1,8-naphthyridin-2(1 H)-one-3-carboxamides

Journal of Medicinal Chemistry

Volumn 57, Issue 21, 2014, Pages 8777-8791

  Lucchesi, Valentina ^a   Hurst, Dow P ^b   Shore, Derek M ^b   Bertini, Simone ^a   Ehrmann, Brandie M ^b   Allarà, Marco ^c   Lawrence, Lyle ^b   Ligresti, Alessia ^c   Minutolo, Filippo ^a   Saccomanni, Giuseppe ^a   Sharir, Haleli ^d   Macchia, Marco ^a   Di Marzo, Vincenzo ^c   Abood, Mary E ^d   Reggio, Patricia H ^b   Manera, Clementina ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF NORTH CAROLINA AT GREENSBORO   (United States)

^c CNR   (Italy)

^d TEMPLE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 HYDROXYETHYL) N (4 METHYLCYCLOHEXYL) 2 OXO 1,2 DIHYDRO 1,8 NAPHTHYRIDINE 3 CARBOXAMIDE; 1 (3 HYDROXYPROPYL) N (4 METHYLCYCLOHEXYL) 2 OXO 1,2 DIHYDRO 1,8 NAPHTHYRIDINE 3 CARBOXAMIDE; 1 (4 FLUOROBENZYL) 6 (4 FLUOROPHENYL) N (4 METHYLCYCLOHEXYL) 2 OXO 1,2 DIHYDRO 1,8 NAPHTHYRIDINE 3 CARBOXAMIDE; 1 (4 FLUOROBENZYL) 6 (4 METHOXYPHENYL) N (4 METHYLCYCLOHEXYL) 2 OXO 1,2 DIHYDRO 1,8 NAPHTHYRIDINE 3 CARBOXAMIDE; 1 (4 FLUOROBENZYL) 6 (FURAN 2 YL) N (4 METHYLCYCLOHEXYL) 2 OXO 1,2 DIHYDRO 1,8 NAPHTHYRIDINE 3 CARBOXAMIDE; 1 (4 FLUOROBENZYL) N (4 METHYLCYCLOHEXYL) 2 OXO 6 (THIOPHEN 2 YL) 1,2 DIHYDRO 1,8 NAPHTHYRIDINE 3 CARBOXAMIDE; 1 (4 FLUOROBUTYL) 1,2 DIHYDRO N (4 METHYLCYCLOHEXYL) 2 OXO 1,8 NAPHTHYRIDINE 3 CARBOXAMIDE; 1 (4 HYDROXYBUTYL) N (4 METHYLCYCLOHEXYL) 2 OXO 1,2 DIHYDRO 1,8 NAPHTHYRIDINE 3 CARBOXAMIDE; 1 (5 FLUOROPENTYL) N (4 METHYLCYCLOHEXYL) 2 OXO 1,2 DIHYDRO 1,8 NAPHTHYRIDINE 3 CARBOXAMIDE; 1 (5 HYDROXYPENTYL) N (4 METHYLCYCLOHEXYL) 2 OXO 1,2 DIHYDRO 1,8 NAPHTHYRIDINE 3 CARBOXAMIDE; 1 (6 FLUOROHEXYL) N (4 METHYLCYCLOHEXYL) 2 OXO 1,2 DIHYDRO 1,8 NAPHTHYRIDINE 3 CARBOXAMIDE; 1 (6 HYDROXYHEXYL) N (4 METHYLCYCLOHEXYL) 2 OXO 1,2 DIHYDRO 1,8 NAPHTHYRIDINE 3 CARBOXAMIDE; 1 BUTYL N (4 METHYLCYCLOHEXYL) 2 OXO 1,2 DIHYDRO 1,8 NAPHTHYRIDINE 3 CARBOXAMIDE; 1,8 NAPHTHYRIDIN 2(1H) ONE 3 CARBOXAMIDE DERIVATIVE; 3 [3 (4 METHYLCYCLOHEXYLCARBAMOYL) 2 OXO 1,8 NAPHTHYRIDINE 1(2H) YL]PROPANOIC ACID; 4 [3 (4 METHYLCYCLOHEXYLCARBAMOYL) 2 OXO 1,8 NAPHTHYRIDINE 1(2H) YL]BUTANOIC ACID; 5 [3 (4 METHYLCYCLOHEXYLCARBAMOYL) 2 OXO 1,8 NAPHTHYRIDINE 1(2H) YL]PENTANOIC ACID; 6 (4 FLUOROPHENYL) N (4 METHYLCYCLOHEXYL) 1 (2 MORPHOLINOETHYL) 2 OXO 1,2 DIHYDRO 1,8 NAPHTHYRIDINE 3 CARBOXAMIDE; 6 (4 METHOXYPHENYL) N (4 METHYLCYCLOHEXYL) 1 (2 MORPHOLINOETHYL) 2 OXO 1,2 DIHYDRO 1,8 NAPHTHYRIDINE 3 CARBOXAMIDE; 6 BROMO 1 (4 FLUOROBENZYL) N (4 METHYLCYCLOHEXYL) 2 OXO 1,2 DIHYDRO 1,8 NAPHTHYRIDINE 3 CARBOXAMIDE; 6 BROMO N (4 METHYLCYCLOHEXYL) 1 (2 MORPHOLINOETHYL) 2 OXO 1,2 DIHYDRO 1,8 NAPHTHYRIDINE 3 CARBOXAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR AFFECTING AGENT; ETHYL 3 [3 (4 METHYLCYCLOHEXYLCARBAMOYL) 2 OXO 1,8 NAPHTHYRIDINE 1(2H) YL]PROPANOATE; ETHYL 4 [3 (4 METHYLCYCLOHEXYLCARBAMOYL) 2 OXO 1,8 NAPHTHYRIDINE 1(2H) YL]BUTANOATE; METHYL 5 [3 (4 METHYLCYCLOHEXYLCARBAMOYL) 2 OXO 1,8 NAPHTHYRIDINE 1(2H) YL]PENTANOATE; N (4 METHYLCYCLOHEXYL) 1 (2 MORPHOLINOETHYL) 2 OXO 6 (THIOPHEN 2 YL) 1,2 DIHYDRO 1,8 NAPHTHYRIDINE 3 CARBOXAMIDE; N (4 METHYLCYCLOHEXYL) 2 OXO 1 PENTYL 1,2 DIHYDRO 1,8 NAPHTHYRIDINE 3 CARBOXAMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; 1,8-NAPHTHYRIDIN-2(1H)-ONE; LIGAND; NAPHTHYRIDINE DERIVATIVE;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MOLECULAR DOCKING; MOLECULAR MODEL; AGONISTS; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; STRUCTURE ACTIVITY RELATION; SYNTHESIS; TUMOR CELL LINE;

CELL LINE, TUMOR; HUMANS; LIGANDS; MODELS, MOLECULAR; MOLECULAR DOCKING SIMULATION; NAPHTHYRIDINES; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84923766732     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm500807e     Document Type: Article

References (42)

1. Velasco, G.; Sanchez, C.; Guzman, M. Towards the use of cannabinoids as antitumour agents Nat. Rev. Cancer 2012, 12, 436-444
2. Pertwee, R. G. Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities Philos. Trans. R. Soc. London B Biol. Sci. 2012, 367, 3353-3363
3. Gaoni, Y.; Mechoulam, R. Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish J. Am. Chem. Soc. 1964, 86, 1646-1647
4. Matsuda, L. A.; Lolait, S. J.; Brownstein, M. J.; Young, A. C.; Bonner, T. I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA Nature 1990, 346, 561-564
5. Munro, S.; Thomas, K. L.; Abu-Shaar, M. Molecular characterization of a peripheral receptor for cannabinoids Nature 1993, 365, 61-65
6. Ameri, A. The effects of cannabinoids on the brain Prog. Neurobiol. 1999, 58, 315-348
7. Das, S. K.; Paria, B. C.; Chakraborty, I.; Dey, S. K. Cannabinoid ligand-receptor signaling in the mouse uterus Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 4332-4336
8. Galiegue, S.; Mary, S.; Marchand, J.; Dussossoy, D.; Carriere, D.; Carayon, P.; Bouaboula, M.; Shire, D.; Le Fur, G.; Casellas, P. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations Eur. J. Biochem. 1995, 232, 54-61
9. Gerard, C. M.; Mollereau, C.; Vassart, G.; Parmentier, M. Molecular cloning of a human cannabinoid receptor which is also expressed in testis Biochem. J. 1991, 279 (Pt 1) 129-134
10. Wenger, T.; Ledent, C.; Csernus, V.; Gerendai, I. The central cannabinoid receptor inactivation suppresses endocrine reproductive functions Biochem. Biophys. Res. Commun. 2001, 284, 363-368
11. Onaivi, E. S.; Ishiguro, H.; Gong, J. P.; Patel, S.; Perchuk, A.; Meozzi, P. A.; Myers, L.; Mora, Z.; Tagliaferro, P.; Gardner, E.; Brusco, A.; Akinshola, B. E.; Liu, Q. R.; Hope, B.; Iwasaki, S.; Arinami, T.; Teasenfitz, L.; Uhl, G. R. Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain Ann. N.Y. Acad. Sci. 2006, 1074, 514-36
12. Battista, N.; Di Tommaso, M.; Bari, M.; Maccarrone, M. The endocannabinoid system: an overview Front. Behav. Neurosci. 2012, 6, 1-7
13. Benito, C.; Nunez, E.; Tolon, R. M.; Carrier, E. J.; Rabano, A.; Hillard, C. J.; Romero, J. Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimers disease brains J. Neurosci. 2003, 23, 11136-11141
14. Cabral, G. A.; Marciano-Cabral, F. Cannabinoid receptors in microglia of the central nervous system: immune functional relevance J. Leukoc. Biol. 2005, 78, 1192-1197
15. Carlisle, S. J.; Marciano-Cabral, F.; Staab, A.; Ludwick, C.; Cabral, G. A. Differential expression of the CB2 cannabinoid receptor by rodent macrophages and macrophage-like cells in relation to cell activation Int. Immunopharmacol. 2002, 2, 69-82
16. Onaivi, E. S.; Ishiguro, H.; Gong, J. P.; Patel, S.; Meozzi, P. A.; Myers, L.; Perchuk, A.; Mora, Z.; Tagliaferro, P. A.; Gardner, E.; Brusco, A.; Akinshola, B. E.; Liu, Q. R.; Chirwa, S. S.; Hope, B.; Lujilde, J.; Inada, T.; Iwasaki, S.; Macharia, D.; Teasenfitz, L.; Arinami, T.; Uhl, G. R. Functional expression of brain neuronal CB2 cannabinoid receptors are involved in the effects of drugs of abuse and in depression Ann. N.Y. Acad. Sci. 2008, 1139, 434-449
17. Roche, M.; Finn, D. P. Brain CB2 Receptors: Implications for Neuropsychiatric Disorders Pharmaceuticals 2010, 3, 2517-2553
18. Cianchi, F.; Papucci, L.; Schiavone, N.; Lulli, M.; Magnelli, L.; Vinci, M. C.; Messerini, L.; Manera, C.; Ronconi, E.; Romagnani, P.; Donnini, M.; Perigli, G.; Trallori, G.; Tanganelli, E.; Capaccioli, S.; Masini, E. Cannabinoid receptor activation induces apoptosis through tumor necrosis factor alpha-mediated ceramide de novo synthesis in colon cancer cells Clin. Cancer. Res. 2008, 14, 7691-7700
19. Manera, C.; Saccomanni, G.; Adinolfi, B.; Benetti, V.; Ligresti, A.; Cascio, M. G.; Tuccinardi, T.; Lucchesi, V.; Martinelli, A.; Nieri, P.; Masini, E.; Di Marzo, V.; Ferrarini, P. L. Rational design, synthesis, and pharmacological properties of new 1,8-naphthyridin-2(1H)-on-3-carboxamide derivatives as highly selective cannabinoid-2 receptor agonists J. Med. Chem. 2009, 52, 3644-3651
20. Rinaldi-Carmona, M.; Barth, F.; Millan, J.; Derocq, J. M.; Casellas, P.; Congy, C.; Oustric, D.; Sarran, M.; Bouaboula, M.; Calandra, B.; Portier, M.; Shire, D.; Breliere, J. C.; Le Fur, G. L. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor J. Pharmacol. Exp. Ther. 1998, 284, 644-650
21. Huffman, J. W.; Liddle, J.; Yu, S.; Aung, M. M.; Abood, M. E.; Wiley, J. L.; Martin, B. R. 3-(1′,1′-Dimethylbutyl)-1-deoxy-delta8-THC and related compounds: synthesis of selective ligands for the CB2 receptor Bioorg. Med. Chem. 1999, 7, 2905-2914
22. Sharir, H.; Console-Bram, L.; Mundy, C.; Popoff, S. N.; Kapur, A.; Abood, M. E. The endocannabinoids anandamide and virodhamine modulate the activity of the candidate cannabinoid receptor GPR55 J. Neuroimmune Pharmacol. 2012, 7, 856-865
23. Manera, C.; Saccomanni, G.; Malfitano, A. M.; Bertini, S.; Castelli, F.; Laezza, C.; Ligresti, A.; Lucchesi, V.; Tuccinardi, T.; Rizzolio, F.; Bifulco, M.; Di Marzo, V.; Giordano, A.; Macchia, M.; Martinelli, A. Rational design, synthesis and anti-proliferative properties of new CB2 selective cannabinoid receptor ligands: an investigation of the 1,8-naphthyridin-2(1H)-one scaffold Eur. J. Med. Chem. 2012, 52, 284-294
24. Li, J.; Edwards, P. C.; Burghammer, M.; Villa, C.; Schertler, G. F. Structure of bovine rhodopsin in a trigonal crystal form J. Mol. Biol. 2004, 343, 1409-1438
25. Okada, T.; Fujiyoshi, Y.; Silow, M.; Navarro, J.; Landau, E. M.; Shichida, Y. Functional role of internal water molecules in rhodopsin revealed by X-ray crystallography Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 5982-5987
26. Palczewski, K.; Kumasaka, T.; Hori, T.; Behnke, C. A.; Motoshima, H.; Fox, B. A.; Le Trong, I.; Teller, D. C.; Okada, T.; Stenkamp, R. E.; Yamamoto, M.; Miyano, M. Crystal structure of rhodopsin: A G protein-coupled receptor Science 2000, 289, 739-745
27. Standfuss, J.; Edwards, P. C.; DAntona, A.; Fransen, M.; Xie, G.; Oprian, D. D.; Schertler, G. F. The structural basis of agonist-induced activation in constitutively active rhodopsin Nature 2011, 471, 656-660
28. McAllister, S. D.; Hurst, D. P.; Barnett-Norris, J.; Lynch, D.; Reggio, P. H.; Abood, M. E. Structural mimicry in class A G protein-coupled receptor rotamer toggle switches: the importance of the F3.36(201)/W6.48(357) interaction in cannabinoid CB1 receptor activation J. Biol. Chem. 2004, 279, 48024-48037
29. McAllister, S. D.; Rizvi, G.; Anavi-Goffer, S.; Hurst, D. P.; Barnett-Norris, J.; Lynch, D. L.; Reggio, P. H.; Abood, M. E. An Aromatic Microdomain at the Cannabinoid CB(1) Receptor Constitutes an Agonist/Inverse Agonist Binding Region J. Med. Chem. 2003, 46, 5139-5152
30. Choe, H. W.; Kim, Y. J.; Park, J. H.; Morizumi, T.; Pai, E. F.; Krauss, N.; Hofmann, K. P.; Scheerer, P.; Ernst, O. P. Crystal structure of metarhodopsin II Nature 2011, 471, 651-655
31. Hurst, D. P.; Grossfield, A.; Lynch, D. L.; Feller, S.; Romo, T. D.; Gawrisch, K.; Pitman, M. C.; Reggio, P. H. A lipid pathway for ligand binding is necessary for a cannabinoid G protein-coupled receptor J. Biol. Chem. 2010, 285, 17954-17964
32. Kobilka, B. K.; Deupi, X. Conformational complexity of G-protein-coupled receptors Trends Pharmacol. Sci. 2007, 28, 397-406
33. Gatley, S. J.; Lan, R.; Pyatt, B.; Gifford, A. N.; Volkow, N. D.; Makriyannis, A. Binding of the non-classical cannabinoid CP 55,940, and the diarylpyrazole AM251 to rodent brain cannabinoid receptors Life Sci. 1997, 61 (14) PL 191-197
34. Huffman, J. W.; Zengin, G.; Wu, M. J.; Lu, J.; Hynd, G.; Bushell, K.; Thompson, A. L.; Bushell, S.; Tartal, C.; Hurst, D. P.; Reggio, P. H.; Selley, D. E.; Cassidy, M. P.; Wiley, J. L.; Martin, B. R. Structure-activity relationships for 1-alkyl-3-(1-naphthoyl)indoles at the cannabinoid CB(1) and CB(2) receptors: steric and electronic effects of naphthoyl substituents. New highly selective CB(2) receptor agonists Bioorg. Med. Chem. 2005, 13 (1) 89-112
35. Bisogno, T.; Cascio, M. G.; Saha, B.; Mahadevan, A.; Urbani, P.; Minassi, A.; Appendino, G.; Saturnino, C.; Martin, B.; Razdan, R.; Di Marzo, V. Development of the first potent and specific inhibitors of endocannabinoid biosynthesis Biochim. Biophys. Acta 2006, 1761 (2) 205-212
36. Cheng, Y.; Prusoff, W. H. Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50% inhibition (I50) of an enzymatic reaction Biochem. Pharmacol. 1973, 22, 3099-3108
37. Ballesteros, J. A.; Weinstein, H. Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors. In Methods in Neurosciences; Stuart, C. S., Ed.; Academic Press: San Diego, CA, 1995; Vol. 25, pp 366-428.
38. Zhang, R.; Hurst, D. P.; Barnett-Norris, J.; Reggio, P. H.; Song, Z. H. Cysteine 2.59(89) in the Second Transmembrane Domain of Human Cb2 Receptor Is Accessible within the Ligand Binding Crevice: Evidence for Possible Cb2 Deviation from a Rhodopsin Template Mol. Pharmacol. 2005, 68, 69-83
39. Song, Z. H.; Slowey, C. A.; Hurst, D. P.; Reggio, P. H. The difference between the CB(1) and CB(2) cannabinoid receptors at position 5.46 is crucial for the selectivity of WIN55212-2 for CB(2) Mol. Pharmacol. 1999, 56, 834-840
40. Tao, Q.; McAllister, S. D.; Andreassi, J.; Nowell, K. W.; Cabral, G. A.; Hurst, D. P.; Bachtel, K.; Ekman, M. C.; Reggio, P. H.; Abood, M. E. Role of a conserved lysine residue in the peripheral cannabinoid receptor (CB2): evidence for subtype specificity Mol. Pharmacol. 1999, 55, 605-613
41. Nebane, N. M.; Hurst, D. P.; Carrasquer, C. A.; Qiao, Z.; Reggio, P. H.; Song, Z. H. Residues accessible in the binding-site crevice of transmembrane helix 6 of the CB2 cannabinoid receptor Biochemistry 2008, 47, 13811-13821
42. Pei, Y.; Mercier, R. W.; Anday, J. K.; Thakur, G. A.; Zvonok, A. M.; Hurst, D.; Reggio, P. H.; Janero, D. R.; Makriyannis, A. Ligand-binding architecture of human CB2 cannabinoid receptor: evidence for receptor subtype-specific binding motif and modeling GPCR activation Chem. Biol. 2008, 15, 1207-1219